Targeted Therapeutic Release via Ultrasound Nanodroplets for Tumor Therapy

Solid tumors present significant treatment challenges due to dense structures and immunosuppressive microenvironment, which limit effective drug and gene delivery. To address this, we present a non-viral, non-invasive, ultrasound-responsive nanodroplet platform designed for targeted delivery and mechanical tumor disruption. We generate stable nanodroplets (<150 nm) with a perfluorohexane core and lipid shell, encapsulating drugs and fluorescent molecules using a microfluidic fabrication system.

Upon exposure to low-intensity focused ultrasound, the nanodroplets undergo acoustic droplet vaporization, transitioning into microbubbles that expand and collapse, which enable localized payload release. When loaded with 5-fluorouracil, the nanodroplets facilitated controlled drug release, reducing cell viability to 7% compared to controls, while in vivo IVIS imaging of fluorescently labeled nanodroplets showed 2.5-fold greater tumor retention versus liver tissue over 24 hours, demonstrated efficient tumor accumulation and localization. Ultrasound imaging confirmed real-time nanodroplets vaporization through a 10 dB signal enhancement. Histological analysis revealed two key findings: precise ultrasound-mediated tumor fractionation, demonstrating a 10-fold increase in tissue disruption compared to controls, and precise delivery of nanodroplets, with fluorescence microscopy showing nanodroplet accumulation (red fluorescence) adjacent to tumor cell nuclei (DAPI staining). These findings validate both the mechanical disruption capability and targeted delivery efficiency of our approach.

This platform combines mechanical tumor disruption, ultrasound-enhanced delivery, and non-viral compatibility. It enables potential gene therapy applications while maintaining precise spatial control. The demonstrated precision in tissue disruption and targeted delivery offers a promising solution for solid tumor treatment.